S&P 500   4,205.54 (+2.02%)
DOW   33,336.60 (+1.72%)
QQQ   323.83 (+2.13%)
AAPL   167.71 (+1.69%)
MSFT   288.70 (+2.27%)
META   177.81 (+5.51%)
GOOGL   119.46 (+2.43%)
AMZN   142.20 (+3.17%)
TSLA   866.00 (+1.88%)
NVDA   174.70 (+2.25%)
NIO   19.73 (+2.92%)
BABA   91.06 (-0.14%)
AMD   96.79 (+1.31%)
MU   59.97 (+1.39%)
T   18.11 (+0.06%)
CGC   3.12 (+8.71%)
GE   76.99 (+2.75%)
F   15.38 (+1.25%)
DIS   110.68 (+2.36%)
AMC   21.89 (-2.49%)
PYPL   97.87 (+3.59%)
PFE   49.67 (-0.22%)
NFLX   240.97 (+4.80%)
S&P 500   4,205.54 (+2.02%)
DOW   33,336.60 (+1.72%)
QQQ   323.83 (+2.13%)
AAPL   167.71 (+1.69%)
MSFT   288.70 (+2.27%)
META   177.81 (+5.51%)
GOOGL   119.46 (+2.43%)
AMZN   142.20 (+3.17%)
TSLA   866.00 (+1.88%)
NVDA   174.70 (+2.25%)
NIO   19.73 (+2.92%)
BABA   91.06 (-0.14%)
AMD   96.79 (+1.31%)
MU   59.97 (+1.39%)
T   18.11 (+0.06%)
CGC   3.12 (+8.71%)
GE   76.99 (+2.75%)
F   15.38 (+1.25%)
DIS   110.68 (+2.36%)
AMC   21.89 (-2.49%)
PYPL   97.87 (+3.59%)
PFE   49.67 (-0.22%)
NFLX   240.97 (+4.80%)
S&P 500   4,205.54 (+2.02%)
DOW   33,336.60 (+1.72%)
QQQ   323.83 (+2.13%)
AAPL   167.71 (+1.69%)
MSFT   288.70 (+2.27%)
META   177.81 (+5.51%)
GOOGL   119.46 (+2.43%)
AMZN   142.20 (+3.17%)
TSLA   866.00 (+1.88%)
NVDA   174.70 (+2.25%)
NIO   19.73 (+2.92%)
BABA   91.06 (-0.14%)
AMD   96.79 (+1.31%)
MU   59.97 (+1.39%)
T   18.11 (+0.06%)
CGC   3.12 (+8.71%)
GE   76.99 (+2.75%)
F   15.38 (+1.25%)
DIS   110.68 (+2.36%)
AMC   21.89 (-2.49%)
PYPL   97.87 (+3.59%)
PFE   49.67 (-0.22%)
NFLX   240.97 (+4.80%)
S&P 500   4,205.54 (+2.02%)
DOW   33,336.60 (+1.72%)
QQQ   323.83 (+2.13%)
AAPL   167.71 (+1.69%)
MSFT   288.70 (+2.27%)
META   177.81 (+5.51%)
GOOGL   119.46 (+2.43%)
AMZN   142.20 (+3.17%)
TSLA   866.00 (+1.88%)
NVDA   174.70 (+2.25%)
NIO   19.73 (+2.92%)
BABA   91.06 (-0.14%)
AMD   96.79 (+1.31%)
MU   59.97 (+1.39%)
T   18.11 (+0.06%)
CGC   3.12 (+8.71%)
GE   76.99 (+2.75%)
F   15.38 (+1.25%)
DIS   110.68 (+2.36%)
AMC   21.89 (-2.49%)
PYPL   97.87 (+3.59%)
PFE   49.67 (-0.22%)
NFLX   240.97 (+4.80%)
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$30.25
+0.53 (+1.78%)
(As of 08/10/2022 10:38 AM ET)
Add
Compare
Today's Range
$29.91
$30.54
50-Day Range
$27.42
$35.80
52-Week Range
$26.85
$65.09
Volume
1,998 shs
Average Volume
666,974 shs
Market Capitalization
$1.51 billion
P/E Ratio
17.90
Dividend Yield
N/A
Price Target
$49.17

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
65.4% Upside
$49.17 Price Target
Short Interest
Bearish
8.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
-0.13mentions of Emergent BioSolutions in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$107,891 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to $2.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

122nd out of 1,108 stocks

Pharmaceutical Preparations Industry

49th out of 542 stocks

EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on EBS shares. Cowen cut their target price on shares of Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Cowen cut their target price on shares of Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Cantor Fitzgerald cut shares of Emergent BioSolutions from an "overweight" rating to a "neutral" rating in a research note on Friday, April 29th. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Saturday, May 7th. Finally, Chardan Capital dropped their price objective on shares of Emergent BioSolutions from $75.00 to $65.00 in a research note on Friday, April 29th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $49.17.

Emergent BioSolutions Price Performance

Shares of NYSE:EBS traded down $0.83 on Tuesday, reaching $29.72. The company's stock had a trading volume of 721,553 shares, compared to its average volume of 666,974. The company has a 50-day simple moving average of $31.48 and a 200 day simple moving average of $36.83. The company has a market cap of $1.48 billion, a P/E ratio of 17.59 and a beta of 0.98. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.38 and a current ratio of 3.92. Emergent BioSolutions has a 52-week low of $26.85 and a 52-week high of $65.09.

Emergent BioSolutions (NYSE:EBS - Get Rating) last released its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($1.24). The firm had revenue of $242.70 million during the quarter, compared to the consensus estimate of $268.77 million. Emergent BioSolutions had a return on equity of 12.22% and a net margin of 6.02%. Emergent BioSolutions's revenue was down 38.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. As a group, equities research analysts anticipate that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.

Insider Transactions at Emergent BioSolutions

In other news, Director Kathryn C. Zoon sold 1,173 shares of the firm's stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the sale, the director now owns 19,654 shares in the company, valued at approximately $619,494.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Kathryn C. Zoon sold 1,173 shares of Emergent BioSolutions stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $31.52, for a total transaction of $36,972.96. Following the completion of the sale, the director now owns 19,654 shares in the company, valued at approximately $619,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kathryn C. Zoon sold 1,996 shares of Emergent BioSolutions stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $35.53, for a total transaction of $70,917.88. Following the sale, the director now owns 12,381 shares of the company's stock, valued at approximately $439,896.93. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
8/01/2022
Today
8/10/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.17
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+62.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$230.90 million
Pretax Margin
8.45%

Debt

Sales & Book Value

Annual Sales
$1.79 billion
Cash Flow
$8.07 per share
Book Value
$30.09 per share

Miscellaneous

Free Float
44,327,000
Market Cap
$1.51 billion
Optionable
Optionable
Beta
0.98

Key Executives

  • Mr. Robert G. Kramer Sr. (Age 65)
    CEO, Pres & Exec. Director
    Comp: $1.93M
  • Mr. Richard S. Lindahl (Age 58)
    Exec. VP, CFO & Treasurer
    Comp: $858.61k
  • Mr. Adam R. Havey (Age 51)
    Exec. VP & COO
    Comp: $843.1k
  • Mr. Atul Saran (Age 49)
    Exec. VP & Chief Strategy and Devel. Officer
    Comp: $820.66k
  • Mr. Robert G. Burrows
    VP of Investor Relations
  • Ms. Jennifer L. Fox
    Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Coleen Glessner
    Exec. VP of Global Quality and Ethics & Compliance
  • Ms. Lynn Kieffer
    VP of Corp. Communications
  • Ms. Katherine Strei (Age 60)
    Exec. VP of HR & Chief HR Officer













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EBS shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month target prices for Emergent BioSolutions' shares. Their EBS share price forecasts range from $30.00 to $77.00. On average, they predict the company's share price to reach $49.17 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How has Emergent BioSolutions' stock performed in 2022?

Emergent BioSolutions' stock was trading at $43.47 on January 1st, 2022. Since then, EBS stock has decreased by 31.6% and is now trading at $29.72.
View the best growth stocks for 2022 here
.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Monday, August, 1st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the consensus estimate of $0.38 by $1.24. The biopharmaceutical company earned $242.70 million during the quarter, compared to analysts' expectations of $268.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 12.22% and a net margin of 6.02%. The business's revenue was down 38.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.33 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $230.00 million-$270.00 million, compared to the consensus revenue estimate of $301.17 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by many different institutional and retail investors. Top institutional investors include Global Alpha Capital Management Ltd. (0.83%), Rice Hall James & Associates LLC (0.52%), Russell Investments Group Ltd. (0.41%), Assenagon Asset Management S.A. (0.28%), Swiss National Bank (0.22%) and Seizert Capital Partners LLC (0.20%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $29.72.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $1.48 billion and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $1.69 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions employs 2,416 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.